Privia Health Group (NASDAQ:PRVA) Stock Price Target Raised at Piper Sandler

Key Points

• Piper Sandler raised its price target on Privia Health to $38 from $36 and maintained an “overweight” rating, implying 60.34% upside from the prior close. Analysts overall rate the stock “Moderate Buy,” with an average target of $31.15.
• Privia reported quarterly EPS of $0.21, beating the $0.09 consensus, and revenue of $656.96 million, up 13.2% year over year and above estimates. The company also raised its 2026 guidance across key financial metrics.
• Potential risks include EPS declining from $0.29 a year earlier, a slim 1.19% net margin, and a reported P/E ratio of 112.86, which could make the stock vulnerable to growth or execution setbacks.

Privia Health Group (NASDAQ:PRVA - Get Free Report) had its price objective raised by equities research analysts at Piper Sandler from $36.00 to $38.00 in a report issued on Friday, Benzinga reports. The brokerage presently has an "overweight" rating on the stock. Piper Sandler's price target points to a potential upside of 60.34% from the company's previous close.

A number of other equities analysts have also recently issued reports on PRVA. Canaccord Genuity Group set a $32.00 price objective on shares of Privia Health Group in a research report on Friday, August 7th. Zacks Research upgraded shares of Privia Health Group from a "strong sell" rating to a "hold" rating in a research report on Wednesday, August 5th. Citigroup reaffirmed a "buy" rating on shares of Privia Health Group in a research note on Thursday, July 23rd. Finally, Weiss Ratings reaffirmed a "hold (c)" rating on shares of Privia Health Group in a research note on Tuesday, September 29th. Eleven research analysts have rated the stock with a Buy rating and three have assigned a Hold rating to the stock. Based on data from MarketBeat.com, Privia Health Group presently has an average rating of "Moderate Buy" and an average target price of $31.15.

Privia Health Group Trading Down 1.0%

PRVA opened at $23.70 on Friday. Privia Health Group has a 1-year low of $18.92 and a 1-year high of $28.82. The business has a 50 day moving average of $20.97 and a 200-day moving average of $22.63. The stock has a market capitalization of $3.03 billion, a price-to-earnings ratio of 112.86 and a beta of 0.76.

Privia Health Group (NASDAQ:PRVA - Get Free Report) last issued its earnings results on Thursday, November 5th. The company reported $0.21 EPS for the quarter, topping the consensus estimate of $0.09 by $0.12. The firm had revenue of $656.96 million during the quarter, compared to the consensus estimate of $610.72 million. Privia Health Group had a return on equity of 3.52% and a net margin of 1.19%. The business's quarterly revenue was up 13.2% on a year-over-year basis. During the same quarter in the previous year, the firm earned $0.29 earnings per share. Equities analysts predict that Privia Health Group will post 0.27 EPS for the current year.

Institutional Trading of Privia Health Group

Several institutional investors have recently added to or reduced their stakes in the stock. BlackRock Inc. acquired a new position in Privia Health Group in the second quarter valued at approximately $550,684,000. Rubicon Founders LLC bought a new position in shares of Privia Health Group during the 2nd quarter worth approximately $153,635,863. Van Berkom & Associates Inc. grew its position in shares of Privia Health Group by 5.4% during the 1st quarter. Van Berkom & Associates Inc. now owns 4,053,043 shares of the company's stock worth $83,371,000 after buying an additional 208,787 shares during the period. Bank of New York Mellon Corp acquired a new stake in shares of Privia Health Group during the 2nd quarter worth approximately $74,425,000. Finally, Dimensional Fund Advisors LP increased its stake in shares of Privia Health Group by 6.3% in the 1st quarter. Dimensional Fund Advisors LP now owns 2,406,717 shares of the company's stock valued at $49,500,000 after acquiring an additional 142,679 shares in the last quarter. 94.48% of the stock is currently owned by institutional investors.

More Privia Health Group News

Here are the key news stories impacting Privia Health Group this week:

• Positive Sentiment: Privia reported Q3 revenue of $656.96 million, up 13.2% year over year and above analysts’ $610.72 million estimate. Earnings per share of $0.21 also topped the $0.09 consensus estimate. Privia Health Q3 results
• Positive Sentiment: The company raised its 2026 guidance across all key financial metrics. Year-to-date adjusted EBITDA reached $114.7 million, a 21.9% increase from the same period in 2025, supporting the case for continued operating growth. Privia Health guidance and results
• Positive Sentiment: A valuation analysis published after the earnings report argues PRVA could be about 24% undervalued, adding a bullish valuation view; this is an estimate, not company guidance. Valuation analysis
• Negative Sentiment: Despite the earnings beat, reported EPS was below the year-ago $0.29 figure. The company’s 1.19% net margin is also slim, while its reported P/E ratio of 114 may leave the stock sensitive to any disappointment in growth or execution.

About Privia Health Group

Privia Health Group, Inc is a physician-enablement company that partners with independent medical practices to support the delivery of coordinated, value-based care. The company provides an integrated platform designed to help physicians manage clinical, administrative and financial functions while maintaining ownership and control of their practices.

Its services include practice management, electronic health record and technology support, revenue-cycle management, payer contracting, population-health analytics, care-management programs and administrative assistance.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.